U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807033) titled 'Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine' on Sept. 02.

Brief Summary: This study included 240 trial participants who had previously taken part in a Phase III clinical trial of an adsorbed tetanus vaccine (Protocol No.: CTP-TTVA-001), with 120 participants in each of the treatment and control groups. All trial participants were required to provide 3.0-4.0 mL of blood for an immunodurability assessment 2.5 years after vaccination.

Study Start Date: Oct. 15

Study Type: OBSERVATIONAL

Condition: Tetanus

Intervention: OTHER: Previously vaccinated with TTVA

3.0 to 4.0 mL of venous blood wi...